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Abstract 
Objective: To evaluate the long term oncological and functional outcomes after 
readaptation of the dorsolateral peritoneal layer following pelvic lymph node 
dissection (PLND) and cystectomy . 
Patients and Methods: A randomised, single-center, single-blinded, two-arm trial 
was conducted on 200 consecutive cystectomy patients who underwent PLND and 
cystectomy for bladder cancer (<cT4, cN0, cM0) between April 2006 and September 
2009. Patients were randomised into two groups: group A with readaptation of the 
dorsolateral peritoneal layer (n=100; 73 male, 27 female; median age 68 yrs, range 
35-86 yrs) and group B without readapation (n=100; 66 male, 34 female; median age 
65 yrs, range 30-86 yrs). Regular postoperative follow-up was performed at our 
outpatient clinic. Median follow-up was 59 months (range 3-100 months), five 
patients were lost to follow-up in group A, seven in group B. Bowel function was 
evaluated using the validated Gastrointestinal Quality of Life Index questionnaire and 
an institutional questionnaire regarding post-cystectomy outcome. Local recurrences 
and distal metastases were evaluated using computed tomography and bone scan at 
the regular follow-up visits.  
Results: There was no significant difference between the two groups in terms of the 
rate of local (pelvic) recurrence (5/95 [5.3%] in group A; 7/93 [7.5%] in group B; p = 
0.53), the rate of distant metastases (21/95 [22.1%] in group A; 23/93 [24.7%] in 
group B; p = 0.67), cancer-specific survival (p = 0.37), and overall survival (p = 0.59).  
Group A had significantly better bowel function at 3 (p < 0.001), 6 (p < 0.006), 12 (p 
<0.006) and 24 months (p = 0.04), and significantly less postoperative abdominal 
pain and bloating at 3 (p = 0.002) and 6 months (p = 0.01). 
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Conclusion: Readaptation of the dorsolateral peritoneal layer following PLND and 
cystectomy has a beneficial long-term impact on bowel function and postoperative 
pain without compromising oncological radicality. 
 
Keywords: bowel function; cystectomy; long-term outcomes; pelvic lymph node 
dissection; prospective randomised trial 
 
Introduction 
Radical cystectomy with extended pelvic lymph node dissection (PLND) and urinary 
diversion - the gold standard treatment for muscle invasive bladder cancer (MIBC) 
(1) - is a major and complex surgical procedure (2, 3). Despite improvements in 
anesthesia, surgical technique, and pre- and postoperative patient management it is 
still burdened by frequent complications. Reported early postoperative complication 
rates (≤ 30 days following surgery) vary from 20% to 58% in recent series (4-7). 
Among these complications, impairment of bowel function (16%-29%) is most 
common (5, 7-10). In 2011 Roth et. al. reported that readaptation of the dorsolateral 
peritoneum parietale at the end of the surgery led to a decrease in postoperative 
pain and earlier recovery of bowel function within the first 30 postoperative days (10). 
This procedure comprises the sparing incision and resection of the dorsolateral 
peritoneum parietale dorsomedially to the external iliac vessels and close to the 
bladder in order to create peritoneal flaps to cover the vessels at the end of the 
operation. Thus, the questions arise as to whether this procedure is safe from an 
oncological point of view and whether the finding of earlier recovery of bowel function 
can translate into long-term improvement of gastrointestinal function. 
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Patients and methods 
Patients 
Between April 2006 and September 2009, 200 patients undergoing (open) radical 
cystectomy, extended PLND and ileal urinary diversion due to bladder cancer (BC) 
at our institution were prospectively enrolled in this study. Patients were randomised 
by a computer-based program without stratification into two groups: group A with 
readaptation of the dorsolateral peritoneal layer (n=100), and group B without 
readaptation (n=100). Exclusion criteria were previous PLND and cT4 MIBC. 
Preoperative patient characteristics did not differ between the two groups (Table 1). 
Median follow-up was 59 months (range: 3 – 100 months). Five patients were lost to 
follow-up in group A, seven in group B (Figure 1). The study was conducted 
according to ethical standards and based on good clinical practice, and was 
approved by the local ethics committee. All patients gave their informed consent.  
 
Surgical technique 
The surgical technique and patient management was described in detail previously 
(10). Briefly, in group A the lateral peritoneum parietale was incised dorsomedially 
and mobilised off the external iliac vessels on both sides to maintain large peritoneal 
flaps for readaptation of the dorsolateral peritoneal layer at the end of surgery 
(Figure 2). In group B, the lateral peritoneum parietale was incised above the 
external iliac artery without creating flaps. The template of our extended PLND 
encompassing the obturator fossa and internal, external, and common iliac lymph 
nodes up to the uretero-iliac junction, and the bowel anastomosis (end to end) were 
standardised and did not differ between the two groups. At least one of three senior 
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staff members was involved in the surgeries in 97% and 99% in group A and B, 
respectively.  
 
Patient management 
Preoperatively, patients were given two high enemas. Oral diet was initiated on 
postoperative day 1 starting with fluids. It was then gradually advanced as tolerated. 
A combined anesthesia (general and epidural) was given intraoperatively, and 
epidural analgesia (1 mg/ml bupivacaine hydrochloride, 2 mcg/ml fentanyl citrate, 
2mcg/ml adrenaline in NaCl 0.9%) was given postoperatively. Fluid administration 
intraoperatively was restricted. To prevent thrombosis low-molecular-weight heparin 
was injected subcutaneously into the arm starting on the evening before surgery. 
 
Outcome measures 
The trial was originally designed to evaluate early postoperative complications and 
postoperative pain as well as gastrointestinal function in the short and long term. 
Early postoperative outcomes (≤ 30 days after surgery) were already published in 
2011 (10) showing an improved recovery of bowel function and fewer complications 
within 30 days following surgery. We are reporting in the present study the long-term 
follow up of this trial in terms of gastrointestinal function as primary outcome 
measures and survival data as secondary outcome measures. 
 
Follow-up 
Patients were followed according to our institutional follow-up protocol as described 
in detail earlier (11). Briefly patients had regular follow-up examinations at our 
outpatient clinic 3, 6, 12 and 24 months following surgery, and annually thereafter. 
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The clinical follow-up included computed tomography and bone scan at 6, 12 and 24 
months and if clinically indicated. Local recurrences were defined as soft tissue mass 
≥ 2cm occurring within the field of PLND and cystectomy below the aortic bifurcation 
(which is inside the bony pelvis). Distant recurrences/metastases were defined as 
those occurring outside the pelvis (12, 13). At the time points 0, 3, 12 and 24 months 
during follow-up patients were asked to responded to the modified validated 
Gastrointestinal Quality of Life Index (GIQLI) questionnaire (14) documenting how 
often they were bothered by different bowel complaints (frequent bowel movements, 
urgent bowel movements, diarrhoea, constipation, and uncontrolled stool loss) as 
described by Fung et. al (15) (Table 2). Additionally at 3, 6, 12 and 24 months 
postoperatively patients were requested to complete our institutional post-
cystectomy gastrointestinal outcome questionnaire regarding stool frequency, need 
for stool regulating medication, constipation, nausea/vomiting, and abdominal 
pain/bloating (Table 3). 
 
Statistical analysis 
Statistical analysis was performed using the Statistical Package for Social Sciences 
(SPSS, version 17, Chicago, IL, USA). Data were labelled as nominal or quantitative 
variables. Nominal variables were characterized by means of frequencies. 
Quantitative variables were tested for normality of distribution applying the 
Kolmogorov-Smirnov test and were described by mean ± standard deviation or 
median and quartiles whenever appropriate for the GIQLI and institutional 
questionnaires. Differences in the median between groups were analyzed using 
Kruskal–Wallis test. The frequencies of nominal variables were compared with the 
chi-square test. Intention to treat analysis provided information about survival from 
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the time of randomisation. Survival analysis was performed using the Kaplan Meyer 
method; the log-rank test was used for univariate comparisons. The level of 
statistical significance was set at p<0.05. Sample size (n = 100 for each group) was 
initially calculated on the basis of a two-sided significance level of 5% and a power of 
80% (α = 0.05; β = 0.2) assuming that the complication rates in group A and B are 
10% and 23%, respectively.  
 
Results 
Survival outcome 
There were no statistically significant differences in overall survival (OS; p = 0.59) 
and cancer specific survival (CSS; p = 0.37) between the two groups; 5-year OS 
rates were 59.9% and 66.7% in groups A and B respectively, CSS rates were 78.9% 
and 76.5% (Figure 3 a and b). The two groups also did not differ significantly in 
terms of the rate of local (pelvic) recurrence (5/95 patients [5.3%] in group A; 7/93 
patients [7.5%] in group B; p = 0.53); and the rate of distant metastases (21/95 
[22.1%] in group A; 23/93 [24.7%] in group B; p = 0.67). Recurrence-free survival 
(RFS; p = 0.64; Figure 3c) and local recurrence-free survival (LRFS; p = 0.61; Figure 
3d) did not differ between the two groups; RFS rates for groups A and B at one year 
and five years were 85.3% and 87.1 %, and 73.7%, and 71% respectively (Figure 
3c) 
 
Functional outcome 
Analysis of the GIQLI questionnaire data showed a statistically significant difference 
between the groups in terms of constipation (at 24 months) and diarrhoea (at 3 
months) in favour of group A patients (Table 2). The institutional questionnaire 
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showed a significantly better outcome after readaptation of the dorsolateral 
peritoneum (group A) in terms of gastrointestinal function (questions Q1-Q4; Table 
3). Moreover, patients in group A experienced significantly less postoperative 
abdominal pain (question Q5) at 3 (p = 0.002) and 6 months ( p = 0.01; Table 3). 
Post-hoc subgroup analysis of our institutional questionnaire showed that the 
improvement in postoperative gastrointestinal function after readaptation of the 
dorsolateral peritoneal layer (group A) was more pronounced on a percentage basis 
in non-orthotopic neobladder patients (ileal conduit, catheterizable pouch) than in 
orthotopic neobladder patients, mainly during the first 6 months after surgery (Tables 
4a and 4b). Subgroup analysis of the GIQLI questionnaire, again, showed better 
results on a percentage basis after readaptation of the dorsolateral peritoneal layer 
in non-orthotopic neobladder patients – although not statistically significant due to 
the low number of patients in this cohort (Tables 5a and 5b).  
 
Discussion 
Closure of the dorsolateral peritoneal layer has a beneficial impact on early (≤ 30 
days) postoperative recovery and early complications following PLND and 
cystectomy (10). We could show that these encouraging short-term results translate 
into long-term improvement of postoperative bowel function and a reduction in 
postoperative pain and bloating without compromising oncological radicality. 
Data on long-term gastrointestinal function after PLND and radical cystectomy is 
scarce and comparison of different urinary diversion techniques is always difficult 
due to the differences in the types and lengths of bowel segment used. Earlier 
studies reported bowel complications after urinary diversion in up to 24% of patients 
over the long-term although no validated questionnaires were used (16, 17). This is 
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in line with our findings showing 29% of all cystectomy patients were bothered at 
least at some time by either constipation, urgent bowel movements and/or stool 
frequency even 24 months after surgery according to the validated Gastrointestinal 
Quality of Life Index Questionnaire (GIQLI) (Table 2). This number is high compared 
to regular “non-cystectomy” populations in which constipation is seen in 2% to 28% 
and irritable bowel disease in 12% (18, 19). Moreover, almost 50% of our cystectomy 
patients complained about postoperative abdominal pain or bloating and needed 
medication for stool regulation after 3 months (Table 3). This is important information 
that must be borne in mind when informing patients about the consequences of 
PLND, cystectomy and urinary diversion. However, as shown in this study, 
gastrointestinal function can be improved by small measures such as readaptation of 
the dorsolateral peritoneum parietale to cover the iliac vessels. Just why 
gastrointestinal function improves after reperitonealisation, however, is not fully 
understood, neither for the early postoperative period nor in the long-term. The 
underlying mechanisms are probably multifactorial. A major factor, however, might 
be a reduction in the number of intra-abdominal adhesions to the pelvic wall and iliac 
vessels resulting from the resection of the covering layer (peritoneum parietale) 
leading at worst to palsy, kinking of bowel segments, constipation, and/or 
mechanical ileus. Other possible factors underlying the impaired postoperative 
gastrointestinal function – at least in the earlier postoperative period - might be an 
inhibitory sympathetic input due to elevated stress reaction, metabolic acidosis with a 
reactive palsy, and/or a release of neurotransmitters, hormones and/or inflammatory 
mediators that might lead to disorganized electrical activity and a lack of coordinated 
propulsion and which therefore might inhibit the motility of the gastrointestinal tract 
(20-24). Because preoperative and postoperative patient management was the same 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
in both groups, we do not think that these factors may have influenced the 
gastrointestinal outcomes. 
Interestingly, subgroup analysis revealed that patients with a non-orthotopic 
diversion (ileal conduit and catheterizable pouch) in particular benefited most from 
readaptation of the dorsolateral peritoneal layer; whereas fewer than 8% of patients 
after reperitonealisation complained of constipation 3 months postoperatively 
irrespective of the urinary diversion, one third of patients complained after non-
orthotopic diversion in the group without reperitonealisation versus only 20% after 
orthotopic neobladder in this group (Table 4). As a consequence, after 
reperitonealisation 20% of patients needed stool-regulating medication 3 months 
postoperative irrespective of the urinary diversion, whereas 80% of patients with 
non-orthotopic diversion needed this medication compared to only 40% of patients 
with orthotopic neobladder without reperitonealisation (Table 4). This difference is 
probably due to the fact that in orthotopic neobladder patients the empty space left 
by resection of the bladder (and to some extent the pelvic lymph nodes) is partly 
covered by the bladder substitute itself, thus leaving much less open wound surface 
in the pelvis, whereas in patients with non-orthotopic diversions small bowel loops 
may adhere more easily to the wound surface without reperitonealisation possibly 
leading to obstruction and delayed gastrointestinal passage. 
Since surgical factors such as the number of lymph nodes removed and positive 
surgical margins influence BC outcomes and especially the rate of local recurrences 
(25), our major concern regarding the present procedure was that sparing of 
peritoneum parietale dorsomedially to the external iliac vessels might leave tumour 
(cells) – detectable only microscopically – in situ which would have fatal 
consequences for the patient in terms of RFS and CSS. Our long-term follow-up, 
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however, found comparable or even favorable rates of local and distal recurrences, 
and no differences in RFS, CSS, and OS compared to other cohorts (26). It can be 
concluded that reperitonealisation is a safe procedure that does not compromise 
oncological safety and radicality. It is of utmost importance, however, that the 
peritoneum is not incised too medially on the tumour-bearing side and thus too close 
to the bladder tumour. The local recurrences rates observed were 5.3% and 7.5% in 
the groups with and without reperitonealisation, respectively. These rates are lower 
than the 7% to 15% rates usually reported (13, 25, 27, 28). Interestingly, most local 
recurrences occurred within 18 months of surgery, although some did occur later 
than 2 years postoperatively (Figure 3d). This finding underscores the importance of 
close follow-up not only during the first 12 to 24 months following surgery, but also 
thereafter (11). 
While a clear benefit in short and long term could be shown after readaptation of the 
dorsolateral peritoneal layer in open radical cystectomy, PLND and urinary diversion, 
the question arises whether it impacts functional recovery following minimally-
invasive surgery. Although purely speculative, we do not see any reason why the 
benefit of improved postoperative results should not translate into the outcomes of 
minimally-invasive techniques, in particular since the template of PLND should be 
the same irrespective of the surgical technique. In addition, a more dorsal incision of 
the lateral peritoneum parietale to create peritoneal flaps can be performed easily in 
minimally-invasive surgery. 
A major limitation of this study is that a considerable number of patients did not 
return the questionnaires. However, return rates of 60% (GIQLI) and 80% 
(institutional post-cystectomy questionnaire) are reasonable numbers and in line with 
returned questionnaire rates in other studies (29, 30). Although return rates of a 
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single questionnaire may have been better, patients were additionally asked to fill out 
our institutional questionnaire because it also assesses pain and serious 
gastrointestinal morbidity (e.g. hospitalisation or surgery for bowel obstruction). 
Another potential limitation is the low number of patients with ileal conduit and 
catheterizable pouch (only 37 % in group A and 35 % in group B), meaning post-hoc 
subgroup analysis of different urinary diversions could be underpowered. However, 
the differences between orthotopic and non-orthotopic diversions within the 
questionnaires were large and clinically plausible. Furthermore, confounding factors 
such as co-medication which might influence bowel function to some extent were not 
routinely assessed in the long term. However, randomisation should create 
comparable groups and thus minimize confounding. Indeed, all baseline 
characteristics did not differ between group A and group B patients.  
In conclusion, readaptation of the dorsolateral peritoneal layer following PLND, 
cystectomy and urinary diversion is a safe procedure that does not compromise 
oncological radicality. The procedure has a beneficial long-term impact on bowel 
function, and leads to a decrease in postoperative pain and bloating 3 and 6 months 
postoperatively. 
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Table 1  
Patient characteristics 
 Group A     
(n = 100) 
Group B     
(n = 100) 
P 
 value 
Gender, n (%)                                         
   Male 73 (73) 66 (66) 0.28 
   Female 27 (27) 34 (34) 
Median age, yrs (range) 68 (35 - 86) 65 (30 - 86) 0.17 
Median BMI (range) 26.2 
(19-41) 
25.3 
(18-40) 
0.75 
Diabetes, n (%) 9 (9) 9 (9) 1 
Chronic constipation, n (%) 12 (12) 9 (9) 0.53 
Prior abdominal surgery, n (%) 34 (34) 22 (22) 0.06 
Neoadjuvant chemotherapy, n (%)                 16 (16) 19 (19) 0.58 
Adjuvant chemotherapy, n (%)                       10 (10) 9 (9) 0.81 
Median operative time, min (range) 390  
(195-490) 
390 
(225-480) 
0.76 
Urinary diversion, n (%)                                   
   Ileal conduit 35 (35) 29 (29) 0.27 
   Orthotopic bladder substitute 63 (63) 65 (65) 
   Catheterizable pouch 2 (2) 6 (6) 
Tumor stage, n (%)  
   pTis/pTa 7 (7) 7 (7) 0.56 
   pT1 13 (13) 21 (21) 
   pT2 29 (29) 30 (30) 
   pT3 41 (41) 32 (32) 
   pT4 10 (10) 10 (10) 
Lymph node involvement, n (%)  
   pN0 75 (75) 70 (70) 0.43 
   pN+ 25 (25) 30 (30) 
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Table 2   
Gastrointestinal function according to the Gastrointestinal Quality of Life Index Questionnaire 
(GIQLI) 
 0 months 
 
3 months 
 
12 months 
 
24 months 
 
How often during the past 2 weeks 
have you been troubled by: 
Group 
A  
n=56 
Group 
B  
n=60 
Group 
A  
n=49 
Group 
B  
n=58 
Group 
A 
 n=41 
Group 
B 
 n=46 
Group 
A 
 n=27 
Group 
B 
 n=31 
Q1: Stool frequency 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
1.8 % 
1.8 % 
8.9 % 
23.2 % 
64.3 %
 
0 % 
1.7 % 
5.0 % 
35.0 % 
58.3 %
 
0 % 
0 % 
12.2 % 
22.4 % 
65.3 %
 
1.7 % 
3.4 % 
6.9 % 
25.9 % 
62.1 %
 
0 % 
4.9 % 
9.8 % 
24.4 % 
61.0 % 
 
2.2 % 
6.5 % 
19.6 % 
15.2 %   
56.5 % 
 
0 % 
3.7 % 
14.8 % 
25.9 % 
55.6 %
 
0 % 
3.2 % 
22.6 % 
3.2 % 
71.0 %
P value  0.63 0.53 0.51 0.07 
Q2: Urgent bowel movements 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
1.8 % 
16.1 % 
16.1 % 
66.1 % 
 
1.7 % 
3.3 % 
23.3 % 
26.7 % 
45.0 % 
 
0 % 
2.0 % 
12.2 % 
34.7 % 
51.0 % 
 
0 % 
5.2 % 
22.4 % 
24.1 % 
48.3 % 
 
0 % 
0 % 
19.5 % 
31.7 % 
48.8 % 
 
0 % 
4.3 % 
23.9 % 
26.1 % 
45.7 % 
 
0 % 
11.1 % 
11.1 % 
33.3 % 
44.4 % 
 
3.2 % 
0 % 
25.8 % 
29.0 % 
41.9 % 
P value  0.19 0.37 0.61 0.16 
Q3: Diarrhea 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
1.8 % 
1.8 % 
8.9 % 
21.4 % 
66.1 % 
 
0 % 
0 % 
6.7 % 
21.7 % 
71.7 % 
 
0 % 
0 % 
26.5 % 
16.3 % 
57.1 % 
 
0 % 
3.4 % 
10.3 % 
37.9 % 
48.3 % 
 
0 % 
0 % 
17.1 % 
26.8 % 
56.1 % 
 
0 % 
6.5 % 
17.4 % 
26.1 % 
50.0 % 
 
3.7 % 
0 % 
18.5 % 
25.9 % 
51.9 % 
 
0 % 
3.2 % 
12.9 % 
22.6 % 
61.3 % 
P value  0.80 0.008 0.46 0.79 
Q4: Constipation 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
7.1 % 
10.7 % 
16.1 % 
66.1 % 
 
1.7 % 
8.3 % 
23.3 % 
11.7 % 
55.0 % 
 
2.0 % 
2.0 % 
10.2 % 
28.6 % 
57.2 % 
 
3.4 % 
5.2 % 
19.0 % 
25.9 % 
46.6 % 
 
0 % 
7.3 % 
2.4 % 
19.5 % 
70.7 % 
 
6.5 % 
0 % 
6.5 % 
26.1 % 
60.9 % 
 
0 % 
7.4 % 
3.7 % 
22.2 % 
66.7 % 
 
3.2 % 
3.2 % 
22.6 % 
35.5 % 
35.5 % 
P value  0.32 0.59 0.09 0.04 
Q5: Uncontrolled stool loss 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
0 % 
3.6 % 
3.6 % 
92.9 % 
 
0 % 
0 % 
1.7 % 
8.3 % 
90.0 % 
 
0 % 
0 % 
2.0 % 
6.1 % 
91.8 % 
 
0 % 
0 % 
3.4 % 
10.3 % 
86.2 % 
 
0 % 
0 % 
2.4 % 
4.9 % 
92.7 % 
 
0 % 
4.3 % 
0 % 
6.5 % 
89.1 % 
 
0 % 
7.4 % 
3.7 % 
7.4 % 
81.5 % 
 
3.2 % 
0 % 
6.5 % 
12.9 % 
77.4 % 
P value  0.50 0.70 0.53 0.53 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3  
Postoperative gastrointestinal function according to our institutional post-cystectomy 
questionnaire 
 
 3 months 6 months 
 
12 months 
 
24 months 
 Group 
A 
n=78 
Group 
B 
n=85 
Group 
A 
n=72 
Group 
B 
n=78 
Group 
A 
n=56 
Group 
B 
n=61 
Group 
A 
n=46 
Group 
B 
n=49 
Q1:How often do you have 
stool/day?  
none  
once 
more than once 
 
9.0 % 
60.3 % 
30.7 % 
 
37.6 % 
38.8 % 
23.6 % 
 
6.9 % 
63.9 % 
29.2 % 
 
25.6 % 
46.2 % 
28.2 % 
 
1.8 % 
62.5 % 
35.7 % 
 
21.3 % 
52.5 % 
26.2 % 
 
6.5 % 
52.2 % 
41.3 % 
 
24.5 % 
49.0 % 
26.5 % 
P value  0.0001 0.005 0.005 0.04
Q2:Did you need medication for 
stool regulation?    
no  
yes 
 
79.5 % 
20.5 % 
 
50.6 % 
49.4 % 
 
91.7 % 
8.3 % 
 
60.3 % 
39.7 % 
 
89.3 % 
10.7 % 
 
63.9 % 
36.1 % 
 
89.1 % 
10.9 % 
 
69.4 % 
30.6 % 
P value  0.0002 0.0001 0.006 0.04
Q3:As a consequence of 
constipation you needed?  
0 (no constipation)  
1 (to see doctor)  
2 (go to hospital) 
3 (have surgery) 
 
93.6 % 
6.4 % 
0 % 
0 % 
 
75.3 % 
18.8 % 
5.9 % 
0 % 
 
97.2 % 
2.8 % 
0 % 
0 % 
 
78.2 % 
16.7 % 
3.8 % 
1.3 % 
 
96.4 % 
1.8 % 
1.8  % 
0 % 
 
85.2 % 
11.5 % 
3.3 % 
0 % 
 
95.7 % 
4.3 % 
0 % 
0 % 
 
83.7 % 
16.3 % 
0 % 
0 % 
P value  0.0004 0.006 0.0001 0.057 
Q4:Do you often feel nausea or 
need to vomit?  
never 
rarely 
often 
 
96.2 % 
0 % 
3.8 % 
 
80.0 % 
2.4 % 
17.6 % 
 
93.1 % 
0 % 
6.9 % 
 
82.1 % 
2.6 % 
15.3 % 
 
94.6 % 
3.6 % 
1.8 % 
 
90.2 % 
3.3 % 
6.5 % 
 
93.5 % 
4.3 % 
2.2 % 
 
91.8 % 
2.1 % 
6.1 % 
P value  0.007 0.05 0.44 0.52 
Q5:Do you often feel abdominal 
pain or bloating?  
never 
rarely 
often 
 
79.5 % 
5.1 % 
15.4 % 
 
54.1 % 
15.3 % 
30.6 % 
 
83.3 % 
1.4 % 
15.3 % 
 
65.4 % 
10.3 % 
24.4 % 
 
82.1 % 
0 % 
17.9 % 
 
75.4 % 
3.3 % 
21.3 % 
 
89.1 % 
0 % 
10.9 % 
 
81.7 % 
6.1 % 
12.2 % 
P value  0.002 0.01 0.44 0.31 
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Table 4  
a) Postoperative gastrointestinal function according to our institutional post-
cystectomy questionnaire for non-orthotopic neobladder patients (ileal conduit and 
catheterizable pouch) 
 
 
 
 
 
 
 
 3 months 6 months 
 
12 months 
 
24 months 
Questionnaire Group 
A 
n=25 
Group 
B 
n=27 
Group 
A 
n=23 
Group 
B 
n=21 
Group 
A 
n=14 
Group 
B 
n=13 
Group 
A 
n=13 
Group 
B 
n=10 
Q1:How often do you have 
stool/day?  
none  
once 
more than once 
 
16.0 % 
64.0 % 
20.0 % 
 
55.6 % 
29.6 % 
14.8 % 
 
17.4 % 
60.9 % 
21.7 % 
 
33.3 % 
47.6 % 
19.0 % 
 
7.1 % 
64.3 % 
28.6 % 
 
23.1 % 
61.5 % 
15.4 % 
 
15.4 % 
38.5 % 
46.2 % 
 
40.0 % 
40.0 % 
20.0 % 
P value  0.01 0.47 0.43 0.29 
Q2:Did you need medication for 
stool regulation?    
no  
yes 
 
80.0 % 
20.0 % 
 
29.6 % 
70.4 % 
 
91.3 % 
8.7 % 
 
38.1 % 
61.9 % 
 
78.6 % 
21.4 % 
 
46.2 % 
53.8 % 
 
76.9 % 
23.1 % 
 
50.0 % 
50.0 % 
P value  0.0001 0.0001 0.08 0.17 
Q3:As a consequence of 
constipation you needed?  
0 (no constipation)  
1 (to see doctor)  
2 (go to hospital) 
3 (have surgery) 
 
92.0 % 
8.0 % 
0 % 
0 % 
 
66.7 % 
25.9 % 
7.4 % 
0 % 
 
100 % 
0 % 
0 % 
0 % 
 
71.4 % 
23.8 % 
4.8 % 
0 % 
 
100 % 
0 % 
0 % 
0 % 
 
76.9 % 
15.4 % 
7.7 % 
0 % 
 
100 % 
0 % 
0 % 
0 %  
 
80.0 % 
20.0 % 
0 % 
0 % 
P value  0.06 0.02 0.16 0.09 
Q4:Do you often feel nausea or 
need to vomit?  
never 
rarely 
often 
 
96 % 
0 % 
4.0 % 
 
66.7 % 
3.7 % 
29.6 % 
 
91.3 % 
0 % 
8.7 % 
 
81.0 % 
4.8 % 
14.3 % 
 
92.9 % 
0 % 
7.1 % 
 
92.3 % 
0 % 
7.7 % 
 
84.6 % 
7.7 % 
7.7 % 
 
80.0 % 
10.0 % 
10.0 % 
P value  0.01 0.46 0.95 0.95 
Q5:Do you often feel abdominal 
pain or bloating?  
never 
rarely 
often 
 
72.0 % 
12.0 % 
16.0 % 
 
37.0 % 
18.6 % 
44.4 % 
 
78.3 % 
0 % 
21.7 % 
 
57.1 % 
9.5 % 
33.3 % 
 
78.6 % 
0 % 
21.4 % 
 
76.9 % 
7.7 % 
15.4 % 
 
92.3 % 
0 % 
7.7 % 
 
90.0 % 
10.0 % 
0 % 
P value  0.03 0.17 0.54 0.35 
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b) Postoperative gastrointestinal function according to our institutional post-
cystectomy questionnaire for orthotopic neobladder patients 
 
 
 3 months 6 months 
 
12 months 
 
24 months 
Questionnaire Group 
A 
n=53 
Group 
B 
n=58 
Group 
A 
n=49 
Group 
B 
n=57 
Group 
A 
n=42 
Group 
B 
n=48 
Group 
A 
n=33 
Group 
B 
n=39 
Q1:How often do you have 
stool/day?  
none  
once 
more than once 
 
5.7 % 
58.5 % 
35.8 % 
 
29.3 % 
43.1 % 
27.6 % 
 
2.0 % 
65.3 % 
32.7 % 
 
22.8 % 
45.6 % 
31,6 % 
 
0 % 
61.9 % 
38.1 % 
 
20.8 % 
50.0 % 
29.2 % 
 
3.0 % 
57.6 % 
39.4 % 
 
20.5 % 
51.3 % 
28.2 % 
P value  0.004 0.005 0.007 0.07 
Q2:Did you need medication for 
stool regulation?    
no  
yes 
 
79.2 % 
20.8 % 
 
60.3 % 
39.7 % 
 
91.8 % 
8.2 % 
 
68.4 % 
31.6 % 
 
92.9 % 
7.1 % 
 
68.8 % 
31.2 % 
 
93.9 % 
6.1 % 
 
74.4 % 
25.6 % 
P value  0.0001 0.005 0.004 0.02 
Q3:As a consequence of 
constipation you needed?  
0 (no constipation)  
1 (to see doctor)  
2 (go to hospital) 
3 (have surgery) 
 
94.3 % 
6.7 % 
0 % 
0 % 
 
79.3 % 
15.5 % 
5.2 % 
0 % 
 
95.9 % 
4.1 % 
0 % 
0 % 
 
80.7 % 
14.0 % 
3.5 % 
1.8 % 
 
95.2 % 
2.4 % 
2.4 % 
0 % 
 
87.5 % 
10.4 % 
2.1 % 
0 % 
 
93.9 % 
6.1 % 
0 % 
0 % 
 
84.6 % 
15.4 % 
0 % 
0 % 
P value  0.03 0.11 0.31 0.21 
Q4:Do you often feel nausea or 
need to vomit?  
never 
rarely 
often 
 
96.2 % 
0 % 
3.8 % 
 
86.2 % 
1.7 % 
12.1 
 
93.9 % 
0 % 
6.1 % 
 
82.4 % 
1.8 % 
15.8 % 
 
95.2 % 
2.4 % 
2.4 % 
 
89.6 % 
2.1 % 
8.3 % 
 
97.0 % 
3.0 % 
0 % 
 
94.9 % 
0 % 
5.1 % 
P value  0.17 0.18 0.47 0.23 
Q5:Do you often feel abdominal 
pain or bloating?  
never 
rarely 
often 
 
83.0 % 
1.9 % 
15.1 % 
 
62.1 % 
13.8 % 
24.1 % 
 
85.7 % 
2.0 % 
12.2 % 
 
68.4 % 
10.5 % 
21.1 % 
 
83.3 % 
0 % 
16.7 % 
 
75.0 % 
2.1 % 
22.9 % 
 
87.9 % 
0 % 
12.1 % 
 
79.5 % 
5.1 % 
15.4 % 
P value  0.01 0.07 0.47 0.37 
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Table 5  
Gastrointestinal function according to Gastrointestinal Quality of Life Index Questionnaire 
(GIQLI) in  
a) Non-orthotopic neobladder patients (ileal conduit, catheterizable pouch) 
 
GIQLI Questionnaire 
 
0 months 
 
3 months 
 
12 months 
 
24 months 
 
How often during the past 2 weeks 
have you been troubled by: 
Group 
A  
n=18 
Group 
B  
n=18 
Group 
A  
n=13 
Group 
B  
n=16 
Group 
A 
 n=10 
Group 
B 
 n=14 
Group 
A 
 n=5 
Group 
B 
 n=8 
Q1: Stool frequency 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
5.6 % 
0 % 
5.6 % 
16.7 % 
72.2 % 
 
0 % 
0 % 
0 % 
38.9 % 
61.1 % 
 
0 % 
0 % 
7.7 % 
23.1 % 
69.2 % 
 
0 % 
6.2 % 
12.5 % 
25 % 
56.2 % 
 
0 % 
0 % 
0 % 
60 % 
40 % 
 
0 % 
14.3 % 
7.1 % 
24.4 % 
57.1 % 
 
0 % 
0 % 
0 % 
40 % 
60 % 
 
0 % 
0 % 
37.5 % 
0 % 
62.5 % 
P value  0.26 0.75 0.18 0.14 
Q2: Urgent bowel movements 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
0 % 
11.1 % 
11.1 % 
77.8 % 
 
0 % 
0 % 
33.3 % 
16.7 % 
50.0 % 
 
0 % 
7.7 % 
7.7 % 
23.1 % 
61.5 % 
 
0 % 
0 % 
25.0 % 
25.0 % 
50.0 % 
 
0 % 
0 % 
20.0 % 
30.0 % 
50.0 % 
 
0 % 
0 % 
28.6 % 
35.7 % 
35.7 % 
 
0 % 
0 % 
20.0 % 
20.0 % 
60.0 % 
 
0 % 
0 % 
50.0 % 
25.0 % 
25.0 % 
P value  0.24 0.49 0.77 0.76 
Q3: Diarrhea 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
0 % 
16.7 % 
11.1 % 
72.2 % 
 
0 % 
0 % 
0 % 
27.8 % 
72.2 % 
 
0 % 
0 % 
15.4 % 
23.1 % 
61.5 % 
 
0 % 
6.2 % 
6.2 % 
25.0 % 
62.5 % 
 
0 % 
0 % 
10.0 % 
20.0 % 
70.0 % 
 
0 % 
14.3 % 
14.3 % 
14.3 % 
57.1 % 
 
0 % 
0 % 
20.0 % 
20.0 % 
60.0 % 
 
0 % 
12.5 % 
12.5 % 
25.0 % 
50.0 % 
P value  0.16 0.70 0.62 0.84
Q4: Constipation 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
11.1 % 
11.1 % 
22.2 % 
55.6 % 
 
0 % 
11.1 % 
27.8 % 
11.1 % 
50.0 % 
 
7.7 % 
7.7 % 
7.7 % 
30.7 % 
46.2 % 
 
12.5 % 
6.2 % 
0 % 
31.3 % 
50 % 
 
0 % 
10.0 % 
10.0 % 
20.0 % 
60.0 % 
 
7.1 % 
0 % 
0 % 
28.6 % 
64.3 % 
 
0 % 
20.0 % 
0 % 
20.0 % 
60.0 % 
 
12.5 % 
12.5 % 
12.5 % 
37.5 % 
25.0 % 
P value  0.56 0.84 0.58 0.91 
Q5: Uncontrolled stool loss 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
0 % 
11.1 % 
5.6 % 
83.3 % 
 
0 % 
0 % 
0 % 
5.6 % 
94.4 % 
 
0 % 
0 % 
0 % 
7.7 % 
92.3 % 
 
0 % 
0 % 
12.5 % 
6.2 % 
81.2 % 
 
0 % 
0 % 
10.0 % 
0 % 
90.0 % 
 
0 % 
14.3 % 
0 % 
7.1 % 
78.6 % 
 
0 % 
20.0 % 
20.0 % 
0 % 
60.0 % 
 
0 % 
0 % 
12.5 % 
25.0 % 
62.5 % 
P value  0.34 0.41 0.30 0.53 
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b) Orthotopic neobladder patients 
 
GIQLI Questionnaire 
 
0 months 
 
3 months 
 
12 months 
 
24 months 
 
How often during the past 2 weeks 
have you been troubled by: 
Group 
A  
n=38 
Group 
B  
n=42 
Group 
A  
n=36 
Group 
B  
n=39 
Group 
A 
 n=30 
Group 
B 
 n=30 
Group 
A 
 n=22 
Group 
B 
 n=23 
Q1: Stool frequency 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
2.6 % 
10.5 % 
26.3 % 
60.5 % 
 
0 % 
2.4 % 
7.1 % 
33.3 % 
57.1 % 
 
0 % 
0 % 
13.9 % 
22.2 % 
63.9 % 
 
2.6 % 
2.6 % 
2.6 % 
25.6 % 
66.7 % 
 
0 % 
6.7 % 
13.3 % 
13.3 % 
66.7 % 
 
0 % 
0 % 
26.7 % 
13.3 % 
60.0 % 
 
0 % 
4.5 % 
18.2 % 
22.7 % 
54.5 % 
 
0 % 
4.3 % 
17.4 % 
4.3 % 
73.9 % 
P value  0.84 0.26 0.34 0.32 
Q2: Urgent bowel movements 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
2.6 % 
18.4 % 
18.4 % 
60.5 % 
 
2.4 % 
4.8 % 
19.0 % 
31.0 % 
42.9 % 
 
0 % 
0 % 
13.9 % 
38.9 % 
47.2 % 
 
0 % 
7.7 % 
20.5 % 
23.1 % 
48.7 % 
 
0 % 
0 % 
20.0 % 
33.3 % 
46.7 % 
 
0 % 
6,7 % 
20.0 % 
23.3 % 
50.0 % 
 
0 % 
13.6 % 
9.1 % 
36.4 % 
40.9 % 
 
4.3 % 
0 % 
17.4 % 
30.4 % 
47.8 % 
P value  0.50 0.21 0.52 0.29 
Q3: Diarrhea 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
2.6 % 
2.6 % 
5.3 % 
26.3 % 
63.2 % 
 
0 % 
0 % 
9.5 % 
19.0 % 
71.4 % 
 
0 % 
0 % 
30.6 % 
13.9 % 
55.6 % 
 
0 % 
2.6 % 
12.8 % 
41.0 % 
43.6 % 
 
0 % 
0 % 
20.0 % 
26.7 % 
53.3 % 
 
0 % 
3.3 % 
16.7 % 
30.0 % 
50.0 % 
 
4.5 % 
0 % 
18.2 % 
27.3 % 
50.0 % 
 
0 % 
0 % 
13.0 % 
21.7 % 
65.2 % 
P value  0.54 0.02 0.66 0.61 
Q4: Constipation 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
5.3 % 
10.5 % 
13.2 % 
71.1 % 
 
2.4 % 
7.1 % 
21.4 % 
11.9 % 
57.1 % 
 
0 % 
0 % 
11.1 % 
27.8 % 
61.1 % 
 
0 % 
2.6 % 
23.1 % 
25.6 % 
48.7 % 
 
0 % 
6.7 % 
0.0 % 
20.0 % 
73.3 % 
 
3.3 % 
0 % 
10.0 % 
26.7 % 
60.0 % 
 
0 % 
4.5 % 
4.5 % 
22.7 % 
68.2 % 
 
0 % 
0 % 
26.1 % 
34.8 % 
39.1 % 
P value  0.57 0.38 0.12 0.04 
Q5: Uncontrolled stool loss 
all the time (0) 
 most of the time (1) 
 sometimes (2) 
rarely (3) 
 never (4) 
 
0 % 
0 % 
0 % 
2.6 % 
97.4 % 
 
0 % 
0 % 
2.4 % 
9.5 % 
88.1 % 
 
0 % 
0 % 
2.8 %  
5.6 % 
91.7 % 
 
0 % 
0 % 
0 % 
12.8 % 
87.2 % 
 
0 % 
0 % 
0 % 
6.7 % 
93.3 % 
 
0 % 
0 % 
0 % 
3.3 % 
96.7 % 
 
0 % 
4.5 % 
0 % 
9.1 % 
86.4 % 
 
4.3 % 
0 % 
4.3 % 
8.7 % 
82.6 % 
P value  0.27 0.33 0.55 0.56
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Group A
with readaptation
Group B
without readaptation
a)
b) e)
c) f)
d)
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Figure 3
a) b)
c) d)
 
 
